Nuevas estrategias en el manejo de casos de infección por tuberculosis, tuberculosis multidrogo resistente y tuberculosis extremadamente resistente
Barra lateral del artículo
Contenido principal del artículo
Resumen
Los fármacos utilizados actualmente en el tratamiento de tuberculosis muestran una efectividad variable respecto a distintas variables, incluyendo la cepa de infección de Mycobacterium tuberculosis que se presente (XDR, MDR), la edad de los pacientes, su raza, el nivel de atención, las comorbilidades presentes, la administración de dosis subóptimas para evitar una dosis tóxica, el riesgo de reinfección, la adherencia al tratamiento, entre otros. Sin embargo, dejando las variables de lado y considerando solo los fármacos actuales, estos tienen un índice de efectividad baja, oscilando entre el 56 % y el 69 % para pacientes que inician tratamiento en una infección MDR-TB. Por lo que existe una necesidad de mejoría en los tratamientos, ya sea con el desarrollo de nuevos fármacos o el uso correcto y no empírico de los fármacos actualmente disponibles.
##plugins.themes.bootstrap3.displayStats.downloads##
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
Referencias
Sayfutdinov Z, Kumar A, Nabirova D, Gadoev J, Turaev L, Sultanov S, et al. Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. International Journal of Environmental Research and Public Health. 2021; 18(6): 2965. https://doi.org/10.3390/ijerph18062965
Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA, et al. Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy. 2020; 64(4). https://doi.org/10.1128/aac.02012-19
Chiang SS, Park S, White EI, Friedman JF, Cruz AT, Del Castillo H, et al. Using Changes in Weight-for-Age z Score to Predict Effectiveness of Childhood Tuberculosis Therapy. Journal of the Pediatric Infectious Diseases Society. 2019; 9(2):150-158. https://doi.org/10.1093/jpids/piy138
Atahan E, Saribas S, Demirci M, Babalık A, Akkus S, Balıkcı A, et al. Evaluating the effectiveness of anti-tuberculosis treatment by detecting Mycobacterium tuberculosis 85B messenger RNA expression in sputum. Journal of Infection and Public Health. 2020; 13(10):1490-1494. https://doi.org/10.1016/j.jiph.2020.05.016
Katoto PD, Musole P, Maheshe G, Bamuleke B, Murhula A, Balungwe P, et al. A miner with no left lung: Extensive pulmonary destruction in delayed effective Multi-Drug-Resistant Tuberculosis treatment. Respiratory Medicine Case Reports. 2020; 31:101234. https://doi.org/10.1016/j.rmcr.2020.101234
Fang Y, Tang Y, Luo Q, Wang N, Tang L, Yang X, et al. Changes of Mycobacterium tuberculosis specific antigen-stimulated CD27−CD38+IFN-γ+CD4+ T cells before and after anti-tuberculosis treatment. European Journal of Medical Research. 2024; 29(1). https://doi.org/10.1186/s40001-024-01713-x
Bhatti Z, Khan AH, Sulaiman SAS, Laghari M, Ali IABH. Determining the risk factors associated with delayed sputum conversion at the end of the intensive phase among tuberculosis patients. Eastern Mediterranean Health Journal. 2021; 27(8):755-763. https://doi.org/10.26719/2021.27.8.755
Butov D, Myasoedov V, Gumeniuk M, Gumeniuk G, Choporova O, Tkachenko A, et al. Treatment effectiveness and outcome in patients with a relapse and newly diagnosed multidrug-resistant pulmonary tuberculosis. Medicinski Glasnik Ljekarske Komore ZeničKo-dobojskog Kantona. 2020; 2. https://doi.org/10.17392/1179-20
Weng T, Sun F, Li Y, Chen J, Chen X, Li R, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infectious Diseases. 2021; 21(1). https://doi.org/10.1186/s12879-021-05870-w
Mansoor H, Hirani N, Chavan V, Das M, Sharma J, Bharati M, et al. Clinical utility of target-based next-generation sequencing for drug-resistant TB. International Journal of Tuberculosis and Lung Disease. Articles Traduits En Français. 2023; 27(1):41-48. https://doi.org/10.5588/ijtld.22.0138
Khan Z, Zhu Y, Guan P, Peng J, Su B, Ma S, et al. Distribution of common and rare drug resistance patterns in Mycobacterium tuberculosis clinical isolates revealed by GenoType MTBDRplus and MTBDRsl assay. Journal of Thoracic Disease. 2023; 15(10):5494-5506. https://doi.org/10.21037/jtd-23-138
Zhdanova E, Goncharova O, Davtyan H, Alaverdyan S, Sargsyan A, Harries AD, et al. 9-12 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. Journal of Infection in Developing Countries. 2019; 15(09.1):66S-74S. https://doi.org/10.3855/jidc.13757
Zhang L, Han X, Ge Q, Shu W, Sun Y, Gao J, et al. Treatment outcomes of retreated patients with isoniazid/rifampicin resistant pulmonary tuberculosis. BMC Infectious Diseases. 2014; 24(1). https://doi.org/10.1186/s12879-023-08909-2
Du L, Zhang Y, Lv X, Duan Y, Shi X, Ji H, et al. Prevalence of Multidrug-Resistant Tuberculosis in Dalian, China: A Retrospective Study. Infection and Drug Resistance. 2021; 14:1037-1047. https://doi.org/10.2147/idr.s294611
Sampiron EG, Calsavara LL, Baldin VP, Montaholi DC, Leme ALD, Namba DY, et al. Isoniazid-N-acylhydrazones as promising compounds for the anti-tuberculosis treatment. Tuberculosis. 2023; 141:102363. https://doi.org/10.1016/j.tube.2023.102363
Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. The Lancet. Infectious Diseases. 2022; 22(7):1042-1051. https://doi.org/10.1016/s1473-3099(21)00811-2
Chen L, Huang H, Yu C, Chien J, Hsueh P. Clinical features and treatment outcomes of Mycobacterium chimaera lung disease and antimicrobial susceptibility of the mycobacterial isolates. Journal of Infection. 2020; 80(4):437-443. https://doi.org/10.1016/j.jinf.2020.01.005
Liu S, Sun Y, Yang R, Ren W, Li C, Tang S. Expression profiling of TRIM gene family reveals potential diagnostic biomarkers for rifampicin-resistant tuberculosis. Microbial Pathogenesis. 2021; 157:104916. https://doi.org/10.1016/j.micpath.2021.104916
Karagoz A, Tutun H, Altintas L, Alanbayi U, Yildirim D, Kocak N. Molecular typing of drug-resistant Mycobacterium tuberculosis strains from Turkey. Journal of Global Antimicrobial Resistance. 2020; 23:130-134. https://doi.org/10.1016/j.jgar.2020.08.012
Garrido-Cardenas J, De Lamo-Sevilla C, Cabezas-Fernández M, Manzano-Agugliaro F, Martínez-Lirola M. Global tuberculosis research and its future prospects. Tuberculosis. 2020; 121:101917. https://doi.org/10.1016/j.tube.2020.101917
Fage D, Aalhoul F, Cotton F. Protein binding investigation of first-line and second-line antituberculosis drugs. International Journal of Antimicrobial Agents. 2023; 62(6):106999. https://doi.org/10.1016/j.ijantimicag.2023.106999
Dwivedi M, Mukhopadhyay S, Yadav S, Dubey KD. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing. Computers in Biology and Medicine. 2022; 146:105607. https://doi.org/10.1016/j.compbiomed.2022.105607
Hung TM, Jayanti RP, Lee HY, Kim H, Mok J, Jang TW, et al. Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohort. International Journal of Antimicrobial Agents. 2023; 62(2):106840. https://doi.org/10.1016/j.ijantimicag.2023.106840
Mutavhatsindi H, et al. Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis. Journal of Infection. 2024; 89(1):106173. https://doi.org/10.1016/j.jinf.2024.106173
Kumari N, Sharma R, Ali J, Chandra G, Singh S, Krishnan MY. The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters. Tuberculosis. 2024; 145:102479. https://doi.org/10.1016/j.tube.2024.102479